This is a preprint.
CD6 Regulates CD4 T Follicular Helper Cell Differentiation and Humoral Immunity During Murine Coronavirus Infection
- PMID: 39091786
- PMCID: PMC11291160
- DOI: 10.1101/2024.07.26.605237
CD6 Regulates CD4 T Follicular Helper Cell Differentiation and Humoral Immunity During Murine Coronavirus Infection
Update in
-
CD6 regulates CD4 T follicular helper cell differentiation and humoral immunity during murine coronavirus infection.J Virol. 2025 Jan 31;99(1):e0186424. doi: 10.1128/jvi.01864-24. Epub 2024 Dec 16. J Virol. 2025. PMID: 39679790 Free PMC article.
Abstract
During activation the T cell transmembrane receptor CD6 becomes incorporated into the T cell immunological synapse where it can exert both co-stimulatory and co-inhibitory functions. Given the ability of CD6 to carry out opposing functions, this study sought to determine how CD6 regulates early T cell activation in response to viral infection. Infection of CD6 deficient mice with a neurotropic murine coronavirus resulted in greater activation and expansion of CD4 T cells in the draining lymph nodes. Further analysis demonstrated that there was also preferential differentiation of CD4 T cells into T follicular helper cells, resulting in accelerated germinal center responses and emergence of high affinity virus specific antibodies. Given that CD6 conversely supports CD4 T cell activation in many autoimmune models, we probed potential mechanisms of CD6 mediated suppression of CD4 T cell activation during viral infection. Analysis of CD6 binding proteins revealed that infection induced upregulation of Ubash3a, a negative regulator of T cell receptor signaling, was hindered in CD6 deficient lymph nodes. Consistent with greater T cell activation and reduced UBASH3a activity, the T cell receptor signal strength was intensified in CD6 deficient CD4 T cells. These results reveal a novel immunoregulatory role for CD6 in limiting CD4 T cell activation and deterring CD4 T follicular helper cell differentiation, thereby attenuating antiviral humoral immunity.
Conflict of interest statement
Competing Interests A.C-B and C.C.B declare no competing interests. F.L. is founder and CSO of Abcon, which focuses on CD6-ADC in the treatment of T cell lymphoma. Abcon was not involved with this manuscript, including experimental design, data acquisition and interpretation.
Figures





References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials